CSS
CRL icon

Cubist Systematic Strategies’s Charles River Laboratories CRL Stock Holding History

Cubist Systematic Strategies’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,065
Closed -$12.2M – 3084
2025
Q2 		$11.7M Buy
+77,065
New +$10.3M 0.05% 526
2023
Q4 		– Sell
-1,962
Closed -$385K – 3674
2023
Q3 		$385K Sell
1,962
-68,566
-97% -$14.1M ﹤0.01% 2464
2023
Q2 		$14.8M Buy
70,528
+33,711
+92% +$6.71M 0.1% 244
2023
Q1 		$7.43M Buy
36,817
+28,072
+321% +$6.36M 0.05% 642
2022
Q4 		$1.91M Sell
8,745
-7,185
-45% -$1.57M 0.01% 1899
2022
Q3 		$3.13M Sell
15,930
-24,975
-61% -$5.39M 0.02% 1545
2022
Q2 		$8.75M Sell
40,905
-14,732
-26% -$3.6M 0.05% 535
2022
Q1 		$15.8M Buy
55,637
+51,204
+1,155% +$15.8M 0.13% 126
2021
Q4 		$1.67M Buy
4,433
+146
+3% +$56.7K 0.02% 1534
2021
Q3 		$1.77M Buy
4,287
+597
+16% +$248K 0.02% 1109
2021
Q2 		$1.36M Sell
3,690
-7,998
-68% -$2.67M 0.02% 1356
2021
Q1 		$3.39M Buy
11,688
+7,865
+206% +$2.19M 0.04% 672
2020
Q4 		$955K Buy
3,823
+1,076
+39% +$256K 0.01% 1415
2020
Q3 		$622K Sell
2,747
-15,581
-85% -$3.23M 0.01% 1611
2020
Q2 		$3.19M Sell
18,328
-1,559
-8% -$249K 0.06% 546
2020
Q1 		$2.51M Buy
19,887
+10,909
+122% +$1.64M 0.07% 395
2019
Q4 		$1.37M Sell
8,978
-3,856
-30% -$534K 0.03% 964
2019
Q3 		$1.7M Sell
12,834
-5,598
-30% -$751K 0.03% 698
2019
Q2 		$2.62M Buy
18,432
+16,009
+661% +$2.17M 0.05% 563
2019
Q1 		$352K Sell
2,423
-18,843
-89% -$2.48M 0.01% 1408
2018
Q4 		$2.41M Buy
21,266
+18,683
+723% +$2.34M 0.11% 215
2018
Q3 		$348K Sell
2,583
-1,511
-37% -$186K 0.02% 1068
2018
Q2 		$460K Buy
+4,094
New +$443K 0.02% 837
2017
Q4 		– Sell
-7,431
Closed -$803K – 1936
2017
Q3 		$803K Buy
7,431
+1,159
+18% +$119K 0.05% 539
2017
Q2 		$634K Buy
6,272
+2,845
+83% +$262K 0.04% 631
2017
Q1 		$308K Sell
3,427
-4,887
-59% -$415K 0.02% 890
2016
Q4 		$633K Buy
8,314
+2,423
+41% +$184K 0.05% 555
2016
Q3 		$491K Buy
5,891
+115
+2% +$9.64K 0.03% 726
2016
Q2 		$476K Sell
5,776
-384
-6% -$31.6K 0.03% 802
2016
Q1 		$468K Sell
6,160
-5,651
-48% -$418K 0.03% 787
2015
Q4 		$949K Buy
11,811
+2,481
+27% +$179K 0.06% 492
2015
Q3 		$593K Sell
9,330
-5,726
-38% -$411K 0.03% 861
2015
Q2 		$1.06M Buy
15,056
+12,328
+452% +$912K 0.05% 536
2015
Q1 		$216K Sell
2,728
-5,761
-68% -$425K 0.01% 1476
2014
Q4 		$540K Buy
8,489
+1,340
+19% +$84K 0.03% 824
2014
Q3 		$427K Sell
7,149
-13,928
-66% -$797K 0.03% 921
2014
Q2 		$1.13M Buy
+21,077
New +$1.16M 0.07% 433

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cubist Systematic Strategies's CRL Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 77,065 shares — an estimated $12.2M sold.

Cubist Systematic Strategies first reported a position in CRL in Q2 2014 and held it in 37 quarters. The position peaked at $15.8M in Q1 2022. 555 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 77,065 Charles River Laboratories shares in Q3 2025, an estimated $12.2M.
  • Cubist Systematic Strategies first reported a position in Charles River Laboratories in Q2 2014 and held it in 37 quarters.
  • Cubist Systematic Strategies's Charles River Laboratories position peaked at $15.8M in Q1 2022.
  • 555 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.